Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857396 | 0.87 | PPARG (0.56) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL9564659 | 0.83 | FFAR1 (0.62) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL8932685 | 0.81 | HDAC8 (0.53) | PPARGFFAR1PPARA | |
| SCHEMBL12515224 | 0.81 | FFAR1 (0.69) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL1072226 | 0.79 | FFAR1 (0.77) | PPARGFFAR1PPARACYP3A4HRH3 | |
| SCHEMBL9312385 | 0.78 | PPARG (0.59) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL19559777 | 0.78 | FFAR1 (0.61) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL9570670 | 0.77 | FFAR1 (0.71) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL7837262 | 0.77 | PPARG (0.50) | PPARGFFAR1PPARA | |
| SCHEMBL9311827 | 0.77 | PPARG (0.64) | PPARGFFAR1PPARACYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942898-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | claimed |
| EP-2001461-A2 | COMBINATION TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1942898-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-07-16 | — | — | EP | claimed |
| EP-1931350-A2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-06-18 | — | — | EP | claimed |
| WO-2007117791-A2 | COMBINATION TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007033265-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2007033266-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2007033350-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2016100301-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015134752-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE AND/OR INJURY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-09-11 | — | — | WO | disclosed |
| EP-2531501-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097079-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | WO | disclosed |
| EP-2346498-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | Metabolex Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2007033265-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033266-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033350-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1483232-A1 | SALTS OF NATEGLINIDE | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076393-A1 | SALTS OF NATEGLINIDE | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |